Armas and Shilpa Enter into a Sales and Distribution Agreement to Bring High quality oncology products to U.S. Market

Monday, October 8, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

Distribution Partnership Agreement

MANALAPAN, N.J. and KARNATAKA, India, Oct. 8,

2018 /PRNewswire-PRWeb/ -- Armas Pharmaceuticals Inc. (Armas), a NJ based pharmaceutical marketing & distribution corporation, and Shilpa Medicare Limited (Shilpa), an India based pharmaceutical company, have
announced today, a distribution partnership agreement. This agreement will encompass various generic oncology injectables and orals within the U.S. market. The first product, an oncology injectable, to be introduced in late October 2018, has an approximate market size of $116 million annually. Armas expects to launch additional oncology products through the 1st quarter of 2019, with a market size totaling more than $430 million annually.

"We are extremely pleased to have an opportunity to partner with Shilpa Medicare Limited, to provide to the US market quality oncology products. Our highly skilled team also looks forward to identifying products for development, utilizing alternative dosage forms, and delivery methods to improve the patient experience.", says John Niemi, President & CEO of Armas.

"We are very excited about this partnership. The combination of Armas' deep customer experience and Shilpa's vertical integration, high quality development and manufacturing capabilities are well suited to launch our portfolio of products approved and under FDA review while providing affordable medicines to patients.", says Adam Levitt, CEO of Shilpa North America.

About Armas Pharmaceuticals, Inc. Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information, please visit ArmasPharmaceuticals.com.

About Shilpa Medicare Limited Shilpa Medicare Limited has its formulation manufacturing facility at Pharma SEZ, Jadcherla, Telangana State, India. It has a state of art manufacturing facility with capability of manufacturing various dosage forms like tablets, capsules & injections according to global regulatory standards. The facility has GMP clearance from Global regulatory authorities viz. US FDA, EU GMP, Brazil-ANVISA, DIGEMID-Peru, WHO GMP etc. The management of the facility is committed to continued compliance with Global GMP requirements. Shilpa Medicare Limited has filed registration dossiers with US FDA, EU Authorities, Latam, GCC, CIS, African countries. The firm also engaged in contract manufacturing. The facility has started commercial supply of the products to different regions of the world – USA, Europe, ROW markets. For more information, please visit vbshilpa.com.

 

SOURCE Armas Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store